With WuXi and Alnylam in tow, Vir enlists NIH as it tests various tools to fight the coronavirus scourge

Natalie Grover

Reporter

George Scangos-led Vir Biotechnology has not only allied with Alnylam to mount a defense against the burgeoning coronavirus crisis, it has also joined forces …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With WuXi and Alnylam in tow, Vir enlists NIH as it tests various tools to fight the coronavirus scourge

Natalie Grover

Reporter

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CMS explains what went into its first round of drug price negotiations

With WuXi and Al­ny­lam in tow, Vir en­lists NIH as it tests var­i­ous tools to fight the coro­n­avirus scourge

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

With WuXi and Alnylam in tow, Vir enlists NIH as it tests various tools to fight the coronavirus scourge

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CMS explains what went into its first round of drug price negotiations